Table 3. Summary of mesothelin-specific T cell responses in the HLA-A1+/HLA-A2+/HLA-A3+ patients treated with the vaccine alone or in sequence with Cy.
| Patient/HLA | COHORT A mesothelin specific T cells/10e6 CD8 T cells Patients Given Immunotherapy alone |
survival (mo) | |||||
|---|---|---|---|---|---|---|---|
| pre | vaccine 3 | vaccine 6 | follow up | follow 2 | follow up 3 | ||
| 1/(2) | 40 | 110 | N/A | N/A | N/A | N/A | 3.36 |
| 2/(1) | 10 | 0 | 0 | N/A | N/A | N/A | 7.1 |
| 3/(3) | 20 | 10 | N/A | N/A | N/A | N/A | 3.36 |
| 4/(3) | 20 | 50 | 100 | 30 | 50 | N/A | 7.9 |
| 5/(1) | 90 | 160 | 110 | N/A | N/A | N/A | 17.6 |
| 6/(2) | 40 | 60 | N/A | N/A | N/A | N/A | 6.1 |
| 7/(2) | 60 | 0 | N/A | N/A | N/A | N/A | 1.7 |
| 8/(2) | 0 | 0 | N/A | N/A | N/A | N/A | 2.86 |
| Patient/HLA |
COHORT B mesothelin specific T cells/10e6 CD8 T cells Patients Given Immunotherapy +Cytoxan |
survival (mo) | |||||
| pre | vaccine 3 | vaccine 6 | follow up | follow up 2 | follow up 3 | ||
| 1/(2) | 50 | 230 | N/A | N/A | N/A | N/A | 3.23 |
| 2/(1) | 10 | 60 | N/A | N/A | N/A | N/A | 22.5 |
| 3/(2) | 110 | 270 | N/A | N/A | N/A | N/A | 6 |
| 4/(2) | 240 | 400 | N/A | N/A | N/A | N/A | 7.73 |
| 5/(3) | 0 | 0 | 210 | 70 | N/A | N/A | 25+ |
| 6/(3) | 70 | 130 | 190 | N/A | N/A | N/A | 8.13 |
| 7/(2) | 0 | 0 | 10 | 10 | N/A | N/A | 13.07 |
| 8/(2) | 130 | 350 | 50 | N/A | N/A | N/A | 3.7 |
| 9/(2) | 30 | 60 | 50 | 30 | 40 | 110 | 12.3 |
| 10/(2) | 50 | 100 | N/A | N/A | N/A | N/A | 2.6 |
Pre= pretreatment #1. Treatment cycle #1 = post treatment #1, vaccine #3 = post treatment #3, vaccine # 6=post treatment #6. NA= Not available due to patient progression. The ELISPOT assay was used to determine the # of mesothelin-specific CD8+ T cells specific for the HLA-A1+ epitope, MesoA1(20-28), HLA-A2+ mesothelin epitope MesoA2(530-539), or the HLA-A3 mesothelin(225-234) epitope. All time points for each patient were assayed simultaneously in six replicates and reported as the mean number of mesothelin specific CD8+ T cells per 106 total CD8+ T cells. Background spots were determined using a negative peptide control known to bind to HLA-A1 HIV- Nef(73-87) (QVPLRPMTY), HLA-A2 HIV-gag(77-85)(SLYNTVATL), and HLA-A3 HIV-1NEF (94-102) (QVPLRPMTYK6). Background spots ranged from 0-10/well. A CEF pool was used as a positive control. The CEF pool contains epitopes from CMV, EBV, and influenza A virus proteins that bind to most HLA class I molecules. CEF pool is obtained from NIH AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: (CEF Control Peptide Pool, 9808) from (DAIDS, NIAID). Positive control spots ranged from 40-1300/per well.